Andrea Moy

Immune checkpoint inhibitor—related dermatologic adverse events

J. Kern, D. Leung, Lacouture, 2020 .

Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement

M. Lacouture, D. Faleck, D. Leung, 2022, Cancers.

Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus

S. Gandhi, O. Hamid, B. A. Costa, 2022, Frontiers in Medicine.

Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide

H. Scher, M. Lacouture, G. Dranitsaris, 2022, The Journal of urology.

Management of immune-related cutaneous adverse events with dupilumab

M. Lacouture, Y. Janjigian, S. Dusza, 2023, Journal for ImmunoTherapy of Cancer.

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients

D. Lake, M. Lacouture, S. Dusza, 2023, Research square.

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

M. Lacouture, D. Faleck, Andrea Moy, 2023, Pharmaceuticals.

Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.

S. Chandarlapaty, M. Robson, M. Lacouture, 2022, Journal of Clinical Oncology.